Related Experiment Videos

Metoprolol succinate extended release/hydrochlorothiazide combination tablets

James W Hainer1, Jennifer Sugg

  • 1AstraZeneca, Wilmington, DE 19803, USA. james.hainer@astrazeneca.com

Vascular Health and Risk Management
|August 21, 2007
PubMed

Insights

Combination therapy using metoprolol succinate extended-release and hydrochlorothiazide (HCT) effectively lowers blood pressure (BP). This antihypertensive regimen offers improved efficacy and tolerability compared to monotherapy.

Area of Science:

  • Pharmacology and Cardiovascular Medicine
  • Drug Development and Therapeutics

Background:

  • Elevated blood pressure (BP) significantly increases the risk of cardiovascular events like stroke and myocardial infarction.
  • Hypertension exhibits heterogeneity, leading to variable patient responses and low efficacy rates with monotherapy.
  • Expert guidelines recommend combination antihypertensive therapy for additive BP-lowering effects.

Purpose of the Study:

  • To evaluate the efficacy and safety of a fixed-dose combination tablet of metoprolol succinate extended-release and hydrochlorothiazide (HCT).
  • To assess the benefits of this combination therapy as an alternative to high-dose monotherapy for hypertension management.

Main Methods:

  • The study leverages the known pharmacokinetic, efficacy, and safety profiles of metoprolol succinate extended-release and hydrochlorothiazide.
  • Pharmacological actions include beta-1 adrenergic blockade (metoprolol) and natriuresis (HCT).

Main Results:

  • The combination product demonstrates superior antihypertensive efficacy compared to monotherapy with either component.
  • This combination facilitates a low-dose multidrug regimen, enhancing patient tolerability.
  • Minimizes the likelihood of dose-related side-effects associated with high-dose monotherapy.

Conclusions:

  • Fixed-dose combination of metoprolol extended-release and hydrochlorothiazide provides enhanced antihypertensive effects.
  • This combination represents a valuable therapeutic option for managing hypertension, improving efficacy and reducing side effects.

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...